Abstract
With the successful use of gefitinib and erlotinib in clinic, some potent EGFR tyrosine kinase receptor inhibitors have gained widespread concern in the treatment of ovarian or non-small-cell lung cancer. However, the emergence of EGFR-activating mutations resist to the drugs, there is an impending need to design new inhibitor targeted EGFR. Furthermore, the understanding of mutual effect between EGFR and drug has been available, it has become a hot spot for the research of anticancer drugs. We have designed and synthesized a series of 6-methoxy-7-(3-morpholinopropoxy)-1-(2- phenoxyethyl)-quinoxalin-2(1H)-one derivatives as novel EGFR inhibitors. Most of the compounds have showed inhibitory activity toward EGFR kinase. This work has demonstrated it is possible to construct a new type of EGFR protein kinase inhibitor using a designin strategy.
Keywords: Anticancer, EGFR inhibitor, kinase assay, molecular docking, quinazolin-2(1H)-one, tyrosine kinase.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Design, Synthesis and Biological Evaluation of Quinoxalin-2(1H)-one Derivatives as EGFR Tyrosine Kinase Inhibitors
Volume: 15 Issue: 2
Author(s): Xuemei Qin, Xiao Han, Liming Hu, Zhipeng Li, Zhufeng Geng, Zhanyang Wang, Chengchu Zeng and Xiangqian Xiao
Affiliation:
Keywords: Anticancer, EGFR inhibitor, kinase assay, molecular docking, quinazolin-2(1H)-one, tyrosine kinase.
Abstract: With the successful use of gefitinib and erlotinib in clinic, some potent EGFR tyrosine kinase receptor inhibitors have gained widespread concern in the treatment of ovarian or non-small-cell lung cancer. However, the emergence of EGFR-activating mutations resist to the drugs, there is an impending need to design new inhibitor targeted EGFR. Furthermore, the understanding of mutual effect between EGFR and drug has been available, it has become a hot spot for the research of anticancer drugs. We have designed and synthesized a series of 6-methoxy-7-(3-morpholinopropoxy)-1-(2- phenoxyethyl)-quinoxalin-2(1H)-one derivatives as novel EGFR inhibitors. Most of the compounds have showed inhibitory activity toward EGFR kinase. This work has demonstrated it is possible to construct a new type of EGFR protein kinase inhibitor using a designin strategy.
Export Options
About this article
Cite this article as:
Qin Xuemei, Han Xiao, Hu Liming, Li Zhipeng, Geng Zhufeng, Wang Zhanyang, Zeng Chengchu and Xiao Xiangqian, Design, Synthesis and Biological Evaluation of Quinoxalin-2(1H)-one Derivatives as EGFR Tyrosine Kinase Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (2) . https://dx.doi.org/10.2174/187152061502150116173357
DOI https://dx.doi.org/10.2174/187152061502150116173357 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Anti-Cancer Agents in Medicinal Chemistry Reverse Screening Bioinformatics Approach to Identify Potential Anti Breast Cancer Targets Using Thymoquinone from Neutraceuticals Black Cumin Oil
Anti-Cancer Agents in Medicinal Chemistry Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention
Anti-Cancer Agents in Medicinal Chemistry Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo
CNS & Neurological Disorders - Drug Targets An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Radioactive Gold Nanoparticle in Two Forms (<sup>198</sup><sub>79</sub>Au GNPs and <sup>99m</sup>Tc-GNPs) for Lung Cancer Antiproliferative Induction and Intralesional Imaging: A Proof of Concept
Anti-Cancer Agents in Medicinal Chemistry Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Pharmacokinetic Research Progress of Anti-tumor Drugs Targeting for Pulmonary Administration
Current Drug Metabolism Dasatinib in the Treatment of Chronic Myeloid Leukemia
Current Signal Transduction Therapy Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors
Current Pharmaceutical Design Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Prediction of Essential Proteins in Prokaryotes by Incorporating Various Physico-chemical Features into the General form of Chou’s Pseudo Amino Acid Composition
Protein & Peptide Letters Synthetic Glycopeptides from the Mucin Family as Potential Tools in Cancer Immunotherapy
Current Cancer Drug Targets A Case Analysis on CT Guided Percutaneous Lung Puncture Biopsy of Lymphocyte Mesenchymal Pneumonia
Combinatorial Chemistry & High Throughput Screening Design, Synthesis and PASS Assisted Evaluation of Novel 2-Substituted Benzimidazole Derivatives as Potent Anthelimintics
Medicinal Chemistry Chitin, Characteristic, Sources, and Biomedical Application
Current Pharmaceutical Biotechnology Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Imaging Primary Brain Tumors by Single-Photon Emission Computerized Tomography (SPECT) with Technetium-99m Sestamibi (MIBI) and Tetrofosmin
Current Medical Imaging Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology